Prothena Corp. (NASDAQ:PRTA) traded down 2% during mid-day trading on Tuesday . The company traded as low as $53.02 and last traded at $53.25, with a volume of 287,851 shares traded. The stock had previously closed at $54.34.

A number of equities research analysts have issued reports on the stock. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Prothena Corp. in a research report on Wednesday, May 4th. Wedbush reaffirmed an “outperform” rating and issued a $77.00 price objective on shares of Prothena Corp. in a research report on Wednesday, August 3rd. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Prothena Corp. in a research report on Friday, June 10th. Barclays PLC assumed coverage on shares of Prothena Corp. in a research report on Friday, May 13th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Zacks Investment Research raised shares of Prothena Corp. from a “sell” rating to a “hold” rating in a research report on Friday, May 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $76.60.

The company’s market cap is $1.72 billion. The firm’s 50-day moving average price is $52.58 and its 200-day moving average price is $43.71.

Prothena Corp. (NASDAQ:PRTA) last posted its earnings results on Tuesday, August 2nd. The company reported ($1.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by $0.27. The firm had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.39 million. Prothena Corp.’s revenue was up 22.2% compared to the same quarter last year. On average, equities analysts anticipate that Prothena Corp. will post ($4.25) EPS for the current year.

In other news, insider Arthur W. Homan sold 9,375 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $52.14, for a total value of $488,812.50. Following the completion of the sale, the insider now directly owns 9,375 shares of the company’s stock, valued at approximately $488,812.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

A number of hedge funds and institutional investors have modified their holdings of PRTA. New York State Common Retirement Fund boosted its position in shares of Prothena Corp. by 4.0% in the fourth quarter. New York State Common Retirement Fund now owns 31,000 shares of the company’s stock worth $2,111,000 after buying an additional 1,200 shares during the period. Wells Fargo & Company MN boosted its position in shares of Prothena Corp. by 2,138.8% in the fourth quarter. Wells Fargo & Company MN now owns 245,639 shares of the company’s stock worth $16,730,000 after buying an additional 234,667 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of Prothena Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 406,677 shares of the company’s stock worth $27,699,000 after buying an additional 1,912 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.